<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03679897</url>
  </required_header>
  <id_info>
    <org_study_id>2018-1117</org_study_id>
    <nct_id>NCT03679897</nct_id>
  </id_info>
  <brief_title>Comparison of 0.375% Ropivacaine and 0.25% Levobupivacaine for Infraclavicular Brachial Plexus Block</brief_title>
  <official_title>0.25% Levobupivacaine Versus 0.375% Ropivacaine: a Comparative Study in Ultrasound-Guided Infraclavicular Brachial Plexus Block</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Asan Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Asan Medical Center</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Infraclavicular brachial plexus block has been used more frequently with the development of
      high-resolution ultrasound. Compared with peripheral nerve block using landmark technique or
      nerve stimulator technique, ultrasound-guided peripheral nerve block decreases the required
      dose of local anesthetics. As the dose of the drug used decreases, the systemic toxic effects
      of local anesthetics are reduced. However, the decreased dose of the drugs might have
      influence on the onset time of local anesthetics. Thus, the investigator aimed to evaluated
      the onset time of the two equipotent local anesthetics, 0.375% ropivacaine and 0.25%
      levobupivacaine.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 18, 2018</start_date>
  <completion_date type="Actual">December 8, 2018</completion_date>
  <primary_completion_date type="Actual">December 7, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>onset time of sensory block</measure>
    <time_frame>up to 40 minutes</time_frame>
    <description>sensory block of 4 nerves(radial, median, ulnar, musculocutaneous nerve) was assessed with pin-prick test every 5 minutes till 40 minutes from the completion of drug injection</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>onset time of motor block</measure>
    <time_frame>up to 40 minutes</time_frame>
    <description>motor block of 4 nerves(radial, median, ulnar, musculocutaneous nerve) was assessed with movement of fingers and elbow every 5 minutes till 40 minutes from the completion of drug injection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>duration of analgesia</measure>
    <time_frame>24 hours</time_frame>
    <description>defined as time for first request by the patient</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">46</enrollment>
  <condition>Regional Anesthesia</condition>
  <arm_group>
    <arm_group_label>Ropivacaine group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BPB with 0.375% ropivacaine solution</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Levobupivacaine group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>BPB with 0.25% levobupivacaine solution</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ropivacaine solution</intervention_name>
    <description>ultrasound-guided infraclavicular brachial plexus block with 0.375% ropivacaine solution</description>
    <arm_group_label>Ropivacaine group</arm_group_label>
    <other_name>rop</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levobupivacaine solution</intervention_name>
    <description>ultrasound-guided infraclavicular brachial plexus block with 0.25% levobupivacaine solution</description>
    <arm_group_label>Levobupivacaine group</arm_group_label>
    <other_name>levo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  American Society of Anesthesiologists physical status 1-3

          -  Patients undergoing upper extremity surgery with infraclavicular brachial plexus block

        Exclusion Criteria:

          -  Patients who do not agree to participate in clinical trial

          -  Patients presenting with neurological deficits of the upper arm, severe coagulopathy,
             chronic renal failure, cardiopulmonary compromise, cerebral vascular disease,
             hypersensitivity to hyaluronidase or local anesthetics or local infection at the site
             of the infraclavicular block, pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Won Uk Koh, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Ulsan, College of Medicine, Asan Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>December 2018</verification_date>
  <study_first_submitted>September 19, 2018</study_first_submitted>
  <study_first_submitted_qc>September 19, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 21, 2018</study_first_posted>
  <last_update_submitted>December 19, 2018</last_update_submitted>
  <last_update_submitted_qc>December 19, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">December 20, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Asan Medical Center</investigator_affiliation>
    <investigator_full_name>Hajung Kim</investigator_full_name>
    <investigator_title>Clinical Instructor</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ropivacaine</mesh_term>
    <mesh_term>Levobupivacaine</mesh_term>
    <mesh_term>Pharmaceutical Solutions</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

